Related Experiment Video

Updated: May 27, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

Guru Sonpavde1, Toni K Choueiri, Bernard Escudier

  • 1Texas Oncology and Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd., Webster, TX 77598, USA. guru.sonpavde@usoncology.com

European Urology
|November 8, 2011
PubMed
Abstract

Insights

For advanced clear cell renal cell carcinoma (RCC), everolimus and axitinib show benefits in progression-free survival (PFS) after first-line vascular endothelial growth factor (VEGF) inhibitors. Patient selection for targeted therapies is key.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Medicine

Background:

  • Advanced clear cell renal cell carcinoma (RCC) treatment has expanded, necessitating optimal patient selection strategies.
  • Investigating second and subsequent line targeted therapies for advanced RCC is crucial.

Purpose of the Study:

  • To analyze second and subsequent line targeted therapies for advanced RCC.
  • To integrate clinical, molecular, and imaging markers for patient selection.
  • To review current treatment paradigms and future directions.

Main Methods:

  • Systematic review of peer-reviewed literature.
  • Analysis of data presented at major scientific conferences.
  • Integration of clinical, molecular, and imaging data.

Main Results:

  • Everolimus and axitinib demonstrated improved progression-free survival (PFS) as second-line therapies after vascular endothelial growth factor (VEGF) inhibitors.
  • Sorafenib, pazopanib, and axitinib extended PFS following cytokine therapy.
  • Biomarker-based patient selection for targeted RCC therapy is under investigation.

Conclusions:

  • Current treatment sequencing for advanced RCC relies on patient and physician decisions.
  • Comorbidities and toxicity profiles influence therapeutic choices.
  • Clinical trials for novel agents and combinations are recommended.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.